Number of years since menopause: Spontaneous bone loss is dependent but response to hormone replacement therapy is independent

Bone

Volumn 30, Issue 4, 2002, Pages 637-642

  H Bjarnason, N ^a   Alexandersen, P ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone loss; Bone mass; Bone turnover; Estrogen; Osteoporosis; Years since menopause

Indexed keywords

ESTRADIOL; ESTRONE SULFATE; GESTODENE; NORETHISTERONE; NORETHISTERONE ACETATE; PIPERAZINE;

ADULT; AGE; ARTICLE; BONE ATROPHY; BONE EXAMINATION; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; FEMUR NECK; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; SPINE; TIME;

AGE FACTORS; BONE DENSITY; CROSS-SECTIONAL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; OSTEOPOROSIS; PROGESTERONE CONGENERS;

EID: 0036210325     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00678-6     Document Type: Article

References (18)

1. Piperazine oestron sulphate and interrupted norethisterone in postmenopausal women: Effects on bone mass, lipoprotein metabolism, climacteric symptoms and adverse effects
2. Low dose estradiol in combination with gestodene to prevent early postmenopausal bone loss
3. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women
4. Applications of an enzyme immuno assay for a new markers of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment
5. Who are candidates for prevention and treatment for osteoporosis?
6. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
7. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
8. Effects of risedronate treatment in vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomised controlled trial
9. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
10. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment
11. Bone response to termination of oestrogen treatment
12. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized controlled trial
13. Effect of risedronate on the risk of hip fracture in elderly women
14. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women
15. Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy X-ray absorptiometry
16. Evidence for two distinct syndromes of involutional osteoporosis
17. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
18. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies